Ajovy Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The ajovy market research report is one of a series of new reports that provides ajovy market statistics, including the ajovy industry global market size, regional shares, competitors with the ajovy market share, detailed ajovy market segments, market trends, and opportunities, and any further data you may need to thrive in the ajovy industry. This ajovy market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing adoption of biologics, rising demand for fast-acting, high-efficacy drugs, advancements in biologic treatments, and rising government regulations for migraine drugs. Major trends in the forecast period include increasing demand for preventive treatment, rising adoption of biologics, telemedicine and digital health integration, personalized and targeted therapies, and increase in self-administration.

The growing prevalence of migraine cases is expected to drive the expansion of the ajovy market in the coming years. Migraine is a neurological disorder characterized by recurring and severe headaches, often accompanied by symptoms such as nausea, vomiting, and heightened sensitivity to light and sound. The rise in migraine cases is attributed to factors including increased stress levels, lifestyle changes, environmental triggers, and genetic predisposition. Ajovy plays a crucial role in managing migraines by reducing the frequency and severity of attacks, providing relief to individuals with chronic or episodic migraines. For example, in March 2024, The House of Commons Library reported that approximately 10 million individuals in the UK are affected by migraines. Additionally, The Migraine Trust highlighted that over one million people experience chronic migraines, enduring symptoms on at least 15 days per month. This growing prevalence underscores the demand for effective treatments like ajovy, fueling market growth.

A significant trend in the ajovy market is the development of advanced monoclonal antibody syringes to enhance usability, ensure accurate dosing, and improve patient adherence to migraine prevention therapies. Monoclonal antibody syringes are pre-filled devices containing lab-engineered antibodies designed to precisely target antigens linked to specific diseases. For instance, Otsuka Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, introduced the AJOVY Subcutaneous Injection 225 mg Syringe, an anti-CGRP monoclonal antibody developed using recombinant DNA technology for migraine prevention. This injection targets the CGRP ligand, blocking its interaction with receptors to reduce migraine frequency. Administered via subcutaneous injection, it offers flexible dosing options - 225 mg every four weeks or 675 mg every 12 weeks - providing patients with greater convenience and positioning it as a distinctive product in its category.

In June 2024, Lotus Pharmaceuticals, a Taiwan-based pharmaceutical company, acquired the Thailand operations of Teva Pharmaceutical for an undisclosed amount. This strategic acquisition aims to bolster Lotus’ presence in Southeast Asia, diversify its portfolio across oncology, women's health, ophthalmology, and respiratory products, and strengthen its distribution in hospital and pharmacy channels. The move is expected to drive sustained profit growth and enhance healthcare accessibility in the region. Teva Pharma (Thailand) Company Limited, a Thailand-based pharmaceutical company, specializes in treatments for migraines and other central nervous system (CNS) disorders.

Major players operating in the ajovy market are Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd.

North America was the largest region in the ajovy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the ajovy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Ajovy is a monoclonal antibody designed to prevent chronic and episodic migraines in adults. It targets and blocks the calcitonin gene-related peptide (CGRP) receptor, a key player in migraine attacks, thereby reducing the frequency, duration, and severity of migraines. This mechanism offers significant relief and enhances the quality of life for patients with chronic migraines.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary clinical indications for ajovy include migraine prevention and cluster headache prevention. The medication is distributed through various channels, including hospitals, clinics, retail pharmacies, and specialty pharmacies. Its end users consist of adult and geriatric patients.

The ajovy market consists of sales of fremanezumab injections, autoinjectors, pre-filled syringes, and pre-mixed injection solutions. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.